Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks ovarian cancer care in real life

NCT ID NCT04830709

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study follows 750 women with advanced ovarian cancer in Germany to see how they are treated in real-world settings. It focuses on the use of PARP inhibitor maintenance therapy after chemotherapy and how it affects outcomes and quality of life. The goal is to learn what works best for patients and doctors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide insights into how well current treatments work in everyday practice and help improve care for ovarian cancer patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may be influenced by differences in patient care across hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

752 people

The number who actually took part.

Started

Jun 2021

Expected to finish

Mar 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Approx. 750 patients with newly diagnosed advanced (FIGO stage III or IV) high-grade epithelial ovarian, fallopian-tube, or primary peritoneal cancer are planned to be included in the study in a consecutive manner

Ages

18 to 130 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed written informed consent 2. Women aged ≥ 18 years 3. Newly diagnosed with primary advanced (FIGO stages III and IV) high-grade epithelial ovarian cancer (including fallopian tube and/or primary peritoneal cancer) 4. For patients who qualify for primary debulking surgery, all surgical procedures must be completed prior to enrollment 5. BRCA mutation test (routinely analyzed germline and/or somatic BRCA1/2 status alone or as part of HRD status determination) already performed or initiated/intended 6. First-line platinum-based chemotherapy planned or a maximum of 3 cycles already received with no sign of disease progression. Total number of cycles after enrollment should be decided individually for each single patient by the treating physician. In case of neoadjuvant chemotherapy and interval debulking surgery, the patient should be enrolled after completion of surgical procedure and at the time of the 1st post-surgery cycle of platinum-based chemotherapy. 7. Willing and able to report PROs electronically 8. Women of childbearing potential must use two forms of reliable contraception according to standard of care Exclusion Criteria: 1\. Pregnancy or breast-feeding 2. Current or planned participation in an interventional clinical trial on first-line treatment of OC 3. Current or upcoming systemic treatment of any tumor other than OC 4. Not eligible for platinum-based chemotherapy or early progress during the cycles of first-line platinum-based chemotherapy prior to enrollment \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

Contacts and locations

Locations

  • Research Site

    Böblingen, Germany, 71032, Germany

  • Research Site

    Göttingen, Germany, 37075, Germany

  • Research Site

    Nürtingen, Germany, 72622, Germany

  • Research Site

    Osnabrück, Germany, 49076, Germany

  • Research Site

    Rotenburg (Wümme), Germany, 27356, Germany

  • Research Site

    Aachen, 52074, Germany

  • Research Site

    Amberg, 92224, Germany

  • Research Site

    Aschaffenburg, 63739, Germany

  • Research Site

    Augsburg, 86156, Germany

  • Research Site

    Bayreuth, 95445, Germany

  • Research Site

    Berlin, 10367, Germany

  • Research Site

    Berlin, 10967, Germany

  • Research Site

    Berlin, 12101, Germany

  • Research Site

    Berlin, 12559, Germany

  • Research Site

    Berlin, 13187, Germany

  • Research Site

    Berlin, 13353, Germany

  • Research Site

    Berlin, 13509, Germany

  • Research Site

    Berlin, 14163, Germany

  • Research Site

    Berlin, 14169, Germany

  • Research Site

    Bielefeld, 33604, Germany

  • Research Site

    Bielefeld, 33611, Germany

  • Research Site

    Bochum, 44791, Germany

  • Research Site

    Bonn, 53113, Germany

  • Research Site

    Borna, 4552, Germany

  • Research Site

    Bottrop, 46236, Germany

  • Research Site

    Brandenburg an der Havel, 14770, Germany

  • Research Site

    Bremen, 28205, Germany

  • Research Site

    Coburg, 96450, Germany

  • Research Site

    Cologne, 50931, Germany

  • Research Site

    Cologne, 50935, Germany

  • Research Site

    Dessau, 6947, Germany

  • Research Site

    Dortmund, 44137, Germany

  • Research Site

    Dresden, 1307, Germany

  • Research Site

    Düsseldorf, 40489, Germany

  • Research Site

    Eggenfelden, 84307, Germany

  • Research Site

    Erfurt, 99084, Germany

  • Research Site

    Fürth, 90766, Germany

  • Research Site

    Gelnhausen, 63571, Germany

  • Research Site

    Gera, 7548, Germany

  • Research Site

    Halle, 6110, Germany

  • Research Site

    Hamburg, 20246, Germany

  • Research Site

    Hamburg, 22307, Germany

  • Research Site

    Hamburg, 22457, Germany

  • Research Site

    Hanau, 63450, Germany

  • Research Site

    Heilbronn, 74078, Germany

  • Research Site

    Hildesheim, 31134, Germany

  • Research Site

    Homburg, 66421, Germany

  • Research Site

    Itzehoe, 25524, Germany

  • Research Site

    Jena, 7747, Germany

  • Research Site

    Kiel, 24116, Germany

  • Research Site

    Krefeld, 47805, Germany

  • Research Site

    Leipzig, 4103, Germany

  • Research Site

    Limburg, 65549, Germany

  • Research Site

    Lübeck, 23562, Germany

  • Research Site

    Magdeburg, 39108, Germany

  • Research Site

    Magdeburg, 39130, Germany

  • Research Site

    Mainz, 55131, Germany

  • Research Site

    Mönchengladbach, 41061, Germany

  • Research Site

    Mutlangen, 73557, Germany

  • Research Site

    München, 80638, Germany

  • Research Site

    Münster, 48145, Germany

  • Research Site

    Nuremberg, 90419, Germany

  • Research Site

    Offenburg, 77654, Germany

  • Research Site

    Pforzheim, 75179, Germany

  • Research Site

    Plauen, 08525, Germany

  • Research Site

    Potsdam, 14467, Germany

  • Research Site

    Recklinghausen, 45659, Germany

  • Research Site

    Regensburg, 93053, Germany

  • Research Site

    Rheine, 48431, Germany

  • Research Site

    Rosenheim, 83022, Germany

  • Research Site

    Rostock, 18059, Germany

  • Research Site

    Saarlouis, 66740, Germany

  • Research Site

    Siegen, 57072, Germany

  • Research Site

    Singen, 78224, Germany

  • Research Site

    Solingen, 42653, Germany

  • Research Site

    Stendal, 39576, Germany

  • Research Site

    Stralsund, 18439, Germany

  • Research Site

    Stuttgart, 70174, Germany

  • Research Site

    Stuttgart, 70199, Germany

  • Research Site

    Torgau, 4860, Germany

  • Research Site

    Traunstein, 83278, Germany

  • Research Site

    Ulm, 89075, Germany

  • Research Site

    Villingen-Schwenningen, 78052, Germany

  • Research Site

    Wiesbaden, 65199, Germany

  • Research Site

    Winnenden, 71364, Germany

  • Research Site

    Witten, 58452, Germany

  • Research Site

    Wolfsburg, 38440, Germany

  • Research Site

    Worms, 67550, Germany

  • Research Site

    Wuppertal, 42283, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.